Key result
The evolution and implementation of cardiac biomarkers, particularly high-sensitivity troponins, have significantly improved the early diagnosis and management of patients with acute coronary syndromes.
This historical review highlights the evolution of cardiac biomarkers from AST to high-sensitivity troponins, emphasizing the latter's role as the current gold standard for diagnosing acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
High-sensitivity troponins remain the ACS diagnostic standard; review confirms consensus while leaving biomarker innovation open for prospective study.
Acute coronary syndrome remains the leading cause of death in both patients with coronary artery disease and patients with other diseases (such as diabetes mellitus, chronic kidney disease, inflammatory diseases of various etiologies, and others). Early diagnosis of cardiomyocyte damage and necrosis opens up wide opportunities to improve the prognosis of patients with atherosclerotic lesions of the coronary arteries, and also makes it possible to discharge patients without acute cardiovascular pathology from intensive care units with a high degree of probability. The article discusses the evolution of the research and introduction into broad clinical practice of markers of myocardial damage and necrosis, which have largely improved modern clinical practice.
No takes yet. Share an insight, caveat, or question.
Окишева et al. (2024) conducted a review in Acute coronary syndrome. Cardiac biomarkers (Troponins, CK-MB, etc.) was evaluated. The evolution and implementation of cardiac biomarkers, particularly high-sensitivity troponins, have significantly improved the early diagnosis and management of patients with acute coronary syndromes.
Synapse has enriched 10 related papers. Consider them for comparative context: